Craig Russell

Dr. Craig Russell


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2013 in Therapeutic Delivery
Verified
Journal Article
Closed access
CRCraig Russell
Craig Russell
ARAyesha Rahman
Ayesha Rahman
Afzal MohammedAfzal Mohammed
Afzal Mohammed
Genomics, proteomics and metabolomics are three areas that are routinely applied throughout the drug-development process as well as after a product enters the market. This review discusses all three 'omics, reporting on the key applications, techniques, recent advances and expectations of each. Genomics, mainly through the use of novel and next-generation sequencing techniques, has advanced areas of drug discovery and development through the comparative assessment of normal and diseased-state tissues, transcription and/or expression profiling, side-effect profiling, pharmacogenomics and the identification of biomarkers. Proteomics, through techniques including isotope coded affinity tags, stable isotopic labeling by amino acids in cell culture, isobaric tags for relative and absolute quantification, multidirectional protein identification technology, activity-based probes, protein/peptide arrays, phage displays and two-hybrid systems is utilized in multiple areas through the drug development pipeline including target and lead identification, compound optimization, throughout the clinical trials process and after market analysis. Metabolomics, although the most recent and least developed of the three 'omics considered in this review, provides a significant contribution to drug development through systems biology approaches. Already implemented to some degree in the drug-discovery industry and used in applications spanning target identification through to toxicological analysis, metabolic network understanding is essential in generating future discoveries.

1 February 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
CCCarlo Curti
Carlo Curti
DKDaniel J. Kirby
Daniel J. Kirby
CRCraig Russell
Craig Russell
Pharmaceutical three-dimensional printing (3DP) is now in its golden age. Recent years have seen a dramatic increase in the research in 3D printed pharmaceuticals due to their potential to deliver highly personalised medicines, thus revolutionising the way medicines are designed, manufactured, and dispensed. A particularly attractive 3DP technology used to manufacture medicines is stereolithography (SLA), which features key advantages in terms of printing resolution and compatibility with thermolabile drugs. Nevertheless, the enthusiasm for pharmaceutical SLA has not been followed by the introduction of novel excipients specifically designed for the fabrication of medicines; hence, the choice of biocompatible polymers and photoinitiators available is limited. This work provides an insight on how to maximise the usefulness of the limited materials available by evaluating how different formulation factors affect printability outcomes of SLA 3D printed medicines. 156 photopolymer formulations were systematically screened to evaluate the influence of factors including photoinitiator amount, photopolymer molecular size, and type and amount of liquid filler on the printability outcomes. Collectively, these factors were found highly influential in modulating the print quality of the final dosage forms. Findings provide enhanced understanding of formulation parameters informing the future of SLA 3D printed medicines and the personalised medicines revolution.

21 March 2020 in Progress in Additive Manufacturing
Verified
Journal Article
Open access
PDF file
CCCarlo Curti
Carlo Curti
Daniel KirbyDaniel Kirby
Daniel Kirby
CRCraig Russell
Craig Russell
Three-dimensional (3D) printing technologies are continuously applied to novel fields, laying the foundations for a new industrial revolution. With regard to pharmaceutical sciences, 3D printed drug products are emerging as attractive and innovative tools in personalised medicine. For example, solid oral dosage forms (e.g. tablets) can be printed in a wide range of dosages, release profiles, geometries and sizes by simply modifying a digital model, thus providing patients with tailored therapies. Various 3D printing technologies have been applied to pharmaceutical manufacture in recent years, and different materials have been investigated to fabricate solid oral dosage forms in a broad range of properties. Therefore, the aim of this review is to describe the state of the art of 3D printing oral pharmaceuticals, with the view to provide formulation scientists with essential information to approach the development of 3D printed drug products, from digital design to final product quality control. Short- to long-term potential areas of application of 3D printed drug products and their relative regulatory pathway challenges are also presented.

25 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CCCarlo Curti
Carlo Curti
Daniel KirbyDaniel Kirby
Daniel Kirby
CRCraig Russell
Craig Russell
Pharmaceutical applications of 3D printing technologies are growing rapidly. Among these, vat photopolymerisation (VP) techniques, including Stereolithography (SLA) hold much promise for their potential to deliver personalised medicines on-demand. SLA 3D printing offers advantageous features for pharmaceutical production, such as operating at room temperature and offering an unrivaled printing resolution. However, since conventional SLA apparatus are designed to operate with large volumes of a single photopolymer resin, significant throughput limitations remain. This, coupled with the limited choice of biocompatible polymers and photoinitiators available, hold back the pharmaceutical development using such technologies. Hence, the aim of this work was to develop a novel SLA apparatus specifically designed to allow rapid and efficient screening of pharmaceutical photopolymer formulations. A commercially available SLA apparatus was modified by designing and fabricating a novel resin tank and build platform able to 3D print up to 12 different formulations at a single time, reducing the amount of sample resin required by 20-fold. The novel SLA apparatus was subsequently used to conduct a high throughput screening of 156 placebo photopolymer formulations. The efficiency of the equipment and formulation printability outcomes were evaluated. Improved time and cost efficiency by 91.66% and 94.99%, respectively, has been confirmed using the modified SLA apparatus to deliver high quality, highly printable outputs, thus evidencing that such modifications offer a robust and reliable tool to optimize the throughput and efficiency of vat photopolymerisation techniques in formulation development processes, which can, in turn, support future clinical applications.

26 June 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
AAAli Al-Khattawi
Ali Al-Khattawi
CRCraig Russell
Craig Russell

9 October 2024 in British Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
MTMohamad Anas Al Tahan
Mohamad Anas Al Tahan
KMKyprianos Michaelides
Kyprianos Michaelides
SNSmith Somasekharan Nair
Smith Somasekharan Nair
SAShouq AlShatti
Shouq AlShatti
CRCraig Russell
Craig Russell
AAAli Al-khattawi
Ali Al-khattawi
Oral administration of protein-based therapeutics is highly desirable due to lower cost, enhanced patient compliance, and convenience. However, the harsh pH environment of the gastrointestinal tract poses significant challenges. Silica-based carriers have emerged as potential candidates for the delivery of protein molecules, owing to their tuneable surface area and pore volume. We explored the use of a commercial mesoporous silica carrier, SYLOID, for the delivery of octreotide and bovine serum albumin (BSA) using a solvent evaporation method in three different solvents. The loading of proteins into SYLOID was driven by diffusion, as described by the Stokes-Einstein equation. Various parameters were investigated, such as protein size, diffusion, and solubility. Additionally, 3D fluorescence confocal imaging was employed to identify fluorescence intensity and protein diffusion within the carrier. Our results indicated that the loading process was influenced by the molecular size of the protein as octreotide exhibited a higher recovery rate (71%) compared to BSA (32%). The methanol-based loading of octreotide showed uniform diffusion into the silica carrier, whereas water and ethanol loading resulted in the drug being concentrated on the surface, as shown by confocal imaging, and further confirmed by scanning electron microscopy (SEM). Pore volume assessment supported these findings, showing that octreotide loaded with methanol had a low pore volume (1.2 cc/g). On the other hand, BSA loading was affected by its solubility in the three solvents, its tendency to aggregate, and its low solubility in ethanol and methanol, which resulted in dispersed particle sizes of 223 and 231 μm, respectively. This reduced diffusion into the carrier, as confirmed by fluorescence intensity and diffusivity values. This study underscores the importance of protein size, solvent properties, and diffusion characteristics when using porous carriers for protein delivery. Understanding these factors allows for the development of more effective oral protein-based therapeutics by enhancing loading efficiency. This, in turn, will lead to advances in targeted drug delivery and improved patient outcomes.